The science of vibration.

How vibration acts on the body

Local vibration is repeated movement applied to a defined area. The body detects that movement through mechanically sensitive structures. In human research, loss-of-function variants in the PIEZO2 ion channel caused marked deficits in vibration detection, discriminative touch and position sense: direct evidence that mechanical input has a biological sensing pathway.[1]

Genital sensation and reflex pathways

A 2024 Nature study identified vibration-sensitive nerve endings within Krause corpuscles in the mouse penis and clitoris. These afferents responded especially well to 40–80 Hz stimulation; experiments manipulating the neurons linked them to sexual reflexes and behavior. This is important biological evidence, but it is animal research, not a human treatment trial. It does not establish an optimal human treatment frequency or validate an MV device.[2]

Muscle sensing is not the same as muscle strengthening

Direct recordings from human nerves show that tendon vibration can drive muscle-spindle activity. These receptors contribute sensory information about muscle state. That observation does not demonstrate that a pelvic device automatically strengthens a weak pelvic floor or relaxes an overactive one; either clinical claim requires its own assessment and outcome evidence.[5]

Local blood flow: a measured response, not a universal explanation

In a 20-person experiment, forearm vibration increased skin blood flow and measured nitric-oxide production in participants with and without type 2 diabetes. The blood-flow response was smaller in the diabetes group. A separate foot study in 11 diabetic and 15 healthy participants found responses that varied with intermittent versus continuous delivery.[6][7]

These experiments support a local vascular response under the tested conditions. They do not establish improved genital circulation, nerve regeneration or lasting recovery from erectile dysfunction with an MV device.

Pain modulation needs its own clinical evidence

In an older controlled crossover study of 72 people with chronic pain syndromes, 48% reported pain alleviation during vibration versus 34% with the placebo unit. The result supports studying a pain-modulating effect, while also showing a substantial nonspecific response. It is not a pelvic-pain trial and should not be used as an MV success rate.[8]

Why the settings and the site matter

“Vibration therapy” is not one standardized intervention. Local genital stimulation, tendon vibration, suprapubic stimulation and whole-body vibration differ in where and how mechanical energy reaches the body. Findings from one should not be transferred to another without supporting research.

Frequency

How many cycles occur each second, measured in hertz (Hz).

Amplitude

The extent of movement. Peak and peak-to-peak measurements are different.

Contact and location

Which tissue receives the input and how the device couples to it.

Timing

Continuous or intermittent stimulation, session duration and repeat use.

The importance of these differences is visible in a 1994 spinal-cord-injury study. At the same 100 Hz frequency, different measured amplitudes produced markedly different ejaculatory responses in an initial 25-person cohort. A subsequent 41-person cohort evaluated the higher-amplitude approach. Frequency alone did not describe the intervention adequately.[3]

Research settings on this page are study descriptions, not treatment instructions. There is no single frequency or protocol established here for every patient, condition or MV device. Use the exact model’s instructions and appropriate clinical guidance.

Clinical evidence by application

The strongest clinical argument is specific: identify the population, the intervention and the outcome. The examples below are selected for relevance and study design, including findings that limit claims of benefit.

Where MV device research fits

MV research asks how targeted stimulation and different device formats may fit particular care needs. It should be read model by model—not as one portfolio-wide efficacy estimate. The clinical evidence library provides the broader collection, including original sources, study designs and disclosures.

Crescendo 2

The Crescendo pain abstract included 21 recruits but only 11 completers; the arousal study combined Crescendo with cognitive behavioral therapy. Neither isolates a Crescendo 2 effect.[14][15] Device-specific evidence →

Poco

MV attributes the vaginismus pilot and pelvic-health randomized trial to Poco. The reviewed publications do not independently establish model identity. Their populations and outcomes differ.[13][12] Poco research context →

Legato

A 14-participant, eight-week conference report evaluated external stimulation alongside education for arousal and lubrication difficulties. It is a small uncontrolled study, not a comparison with established treatments.[16] Legato research context →

Tenuto 2

A 16-person conference report combined Tenuto 2 with tadalafil and a penile pump after prostatectomy. Mean erectile-function scores were 22 before surgery and 19 six months afterward—not an improvement from 11 to 19. Without a control group, the device’s contribution cannot be isolated.[17] Tenuto 2 evidence →

Tenuto Mini

A preliminary psychogenic-ED ring evaluation was published as journal correspondence, not a randomized trial. Constriction and vibration may contribute together; observed outcomes cannot automatically be assigned to vibration alone.[18] Tenuto Mini evidence →

Molto

An IDEAL Stage 1 conference report explored use in two men with chronic non-bacterial prostatitis. It is early feasibility research, not evidence of a broadly established prostatitis treatment or an additional US indication.[19] Molto research context →

Engineering and clinical evidence answer different questions. Adaptable shapes, materials and controls describe how a device is built; they do not, on their own, establish a clinical outcome. Explore the internal device architecture →

Prof. Dasgupta’s urological vibration research

MV Health’s Chief Medical Officer, Prof. Prokar Dasgupta, has a documented research connection to vibration in urology that predates the company. In 1997, he was first author of the Queen Square bladder-stimulator study with C. Haslam, R. Goodwin and C. J. Fowler.[20]

The Queen Square study · 1997

The study evaluated suprapubic vibration in 36 people with neurological disease, including 29 with multiple sclerosis. At a mean follow-up of 11.5 months, 25 of 36 reported symptom improvement; mean post-void residual urine volume fell from 175 to 68 mL. The report also identified patients for whom it was not useful, including those with suprapubic numbness, more severe disability or very high residual volumes.[20]

This was an uncontrolled study of a different device for neurogenic bladder emptying. It is not evidence that current MV products treat urinary retention, and it is not a reason to replace a prescribed catheterization plan.

More recently, Dasgupta co-authored the 2025 two-patient Molto prostatitis abstract. Both patients reported pain scores changing from 7/10 to 3/10 over the reported follow-up. The abstract states that industry supplied the devices and had no other study role. These observations are hypothesis-generating, not confirmatory evidence.[19]

Transparency: this is an MV Health educational page, and Prof. Dasgupta is the company’s Chief Medical Officer. His expertise and authorship provide relevant context, not independent validation of every device or clinical claim. Read his biography →

More than a century of investigation

The historical record is real. The scientific standards and clinical applications have changed substantially. The milestones below illustrate that progression; they are not a continuous chain of proven efficacy.

1. 1883

   Mechanical vibration in medical writing

   J. Mortimer Granville published a monograph on nerve vibration and excitation as therapeutic approaches. The digitized original documents nineteenth-century medical interest—not controlled evidence for modern sexual-health devices.[21]

2. 1981

   A specific urological application

   G. S. Brindley published a report on reflex ejaculation under vibratory stimulation in men with paraplegia.[22]

3. 1994–1997

   Parameters and patient selection

   Research examined the importance of amplitude in penile stimulation and the Queen Square device’s use in selected neurological patients.[3][20]

4. 2014

   Randomized testing

   A post-prostatectomy trial tested clinical benefit against a control group—and did not establish a statistically significant effect.[10]

5. 2024

   Genital sensory biology

   Mouse experiments characterized Krause corpuscles as vibration-sensitive structures involved in sexual behavior.[2]

6. 2026

   Application-specific evidence continues

   Current urology guidance supports specialist sperm-retrieval techniques, while new pelvic-health trial findings add short-term comparative data.[4][12]

Historical precedent is not a regulatory predicate

In FDA terminology, a predicate is a legally marketed device used for a substantial-equivalence comparison in the 510(k) process. Sharing the principle of vibration, or having existed for decades, does not establish that relationship. No historical instrument on this page is presented as an FDA predicate for an MV device.[23]

Safety and responsible interpretation

Non-drug does not mean risk-free. The EAU guideline specifically warns about autonomic dysreflexia during sexual stimulation and ejaculation in people with spinal cord injury, especially at or above T6. Specialist evaluation and an appropriate safety plan are essential in that setting.[4]

For device use, follow current model-specific precautions and care instructions. Persistent pain, altered sensation, injury, bleeding or unexplained changes in sexual or urinary function warrant clinical assessment. This overview does not provide a stimulation prescription or replace device-care guidance.

• Match the evidence. The same device, generation, population, placement and co-interventions matter.
• Separate outcomes. Arousal, orgasm, semen retrieval, pain, erection quality and durable recovery are different endpoints.
• Read the denominator. Results among completers can differ from results across everyone enrolled.
• Keep uncertainty visible. An abstract, case report or exploratory series is not equivalent to a well-controlled confirmatory trial.
• Look beyond statistical significance. Magnitude, durability, harms, patient priorities and comparison with usual care also matter.

The defensible conclusion is that local vibration is a biologically active form of stimulation with established specialist applications and promising—but uneven—evidence across other uses. A device’s clinical role must be justified for the particular question being asked.